Lauren E. Dias

TL;DR: Re recombinant maspin protein blocks the motility of mammary carcinoma cells in culture over 12 h, as demonstrated by time-lapse video microscopy.

TL;DR: The use of FOLFIRINOX was associated with conversion to resectability in >20% of patients and the toxicities observed with the use of this regimen raise important questions about how to best treat patients with LAPC.

TL;DR: Issues of support, abandonment, and how hope is conveyed are discussed, and the literature that informs good clinical practice in breaking bad news is reviewed.

TL;DR: In a non-clinical trial setting, FOLFIRINOX demonstrated activity in both the metastatic and locally-advanced settings, and appears to be associated with manageable, but significant toxicities, with over 40% of patients requiring hospitalization.

TL;DR: The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program has documented large secular changes in incidence of invasive colorectal cancer between 1973 through the present day and increases in use, by the population, of non-steroidal anti-inflammatory drugs (NSAIDs).